Nordic Life Science 1
TOP STORIES BUSINESS INVESTMENT new ways to REPOR
T support healthier urban populations and will draw on the university’s expertise in public health research and education programs to impact the global fight against diabetes and other serious chronic diseases. Based at the University of Toronto Mississauga, the new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and University of Toronto Mississauga. “One hundred years after the discovery of insulin, we’re proud to once again partner with the University of Toronto with the ambition of helping society to address the root causes of type 2 diabetes and obesity,” says Lars Fruergaard Jørgensen, CEO, Novo Nordisk. consultancy company limited their analysis to companies categorized as pharmaceutical/medicine companies on nyemissioner.se. The companies had to have operations that were clearly defined as pharmaceutical or medical technology and that had their headquarters in Sweden. “We also examined Vantage’s report ‘Pharma, Biotech and Medtech in review HY2020’ to understand what global raised capital from private investors in the form of venture capital looked like,” says Carolin Wiken, partner, Paues Åberg. The analysis showed that investments in pharmaceutical companies in the form of rights issues increased by 11 percent between 2018 and 2019 (about 7 billion SEK invested) and 49 percent between 2019 and 2020 (about 10.5 billion SEK invested). For medtech companies, the difference was significantly higher percentage-wise: up 62 percent between 2018 and 2019 (corresponding to 3.1 billion SEK invested) and an impressive increase of 109 percent between 2019 and 2020 (corresponding to about 6.6 billion SEK). In other words, there was a 235 percent increase between 2018 and 2020 (1.94 billion SEK was invested in December 2018 and 6.5 billion SEK in December 2020). Lars Fruergaard Jørgensen, CEO, Novo Nordisk 12 NORDICLIFESCIENCE.ORG PHOTO GETINGE HYBRID ORS